Noura Shingo, Yamamoto Hirofumi, Ohnishi Tadashi, Masuda Norikazu, Matsumoto Takashi, Takayama Osamu, Fukunaga Hiroki, Miyake Yasuhiro, Ikenaga Masakazu, Ikeda Masataka, Sekimoto Mitsugu, Matsuura Nariaki, Monden Morito
Department of Surgery and Clinical Oncology, Graduate School of Medicine, Osaka University, Japan.
J Clin Oncol. 2002 Oct 15;20(20):4232-41. doi: 10.1200/JCO.2002.10.023.
Inconsistent conclusions have been drawn about the clinical significance of micrometastases in lymph nodes (LNs) of node-negative colorectal cancer (CRC) patients. We performed a comparative study of detection of micrometastases using immunohistochemistry (IHC) by anti-cytokeratin antibody and carcinoembryonic antigen (CEA)-specific reverse-transcriptase polymerase chain reaction (RT-PCR) in the same patients, in an attempt to move closer to their clinical application.
Sixty-four CRC patients, with RNA of good quality available from paraffin-embedded LN specimens, were selected from 84 stage II patients who underwent curative surgery between 1988 and 1996. We investigated associations between the presence of micrometastases by each method and prognosis.
Micrometastases were detected in 19 (29.6%) of 64 patients by RT-PCR and in 35 (54.7%) of 64 patients by IHC. By RT-PCR analysis, patients exhibiting a positive band for CEA mRNA had a significantly worse prognosis than those who were RT-PCR-negative, with respect to both disease-free and overall survival (P =.027 and.015, respectively). By IHC analysis, the presence of micrometastasis did not predict patient outcome in terms of either disease-free or overall survival. Infiltrating pattern of tumor growth characteristic was significantly associated with shorter disease-free survival among various clinical or pathologic factors. By multivariate Cox regression analysis, micrometastasis detected by RT-PCR and the Crohn's-like lymphoid reaction were both independent prognostic factors.
Micrometastases detected by RT-PCR, but not IHC, may be of clinical value in identifying patients who may be at high risk for recurrence of CRC and who are therefore likely to benefit from systemic adjuvant therapy.
关于淋巴结微转移在无淋巴结转移的结直肠癌(CRC)患者中的临床意义,已得出不一致的结论。我们在同一组患者中使用抗细胞角蛋白抗体免疫组化(IHC)和癌胚抗原(CEA)特异性逆转录聚合酶链反应(RT-PCR)对微转移检测进行了一项比较研究,试图更接近其临床应用。
从1988年至1996年间接受根治性手术的84例II期患者中,选取64例可从石蜡包埋的淋巴结标本中获得高质量RNA的CRC患者。我们研究了每种方法检测到的微转移的存在与预后之间的关联。
通过RT-PCR在64例患者中的19例(29.6%)检测到微转移,通过IHC在64例患者中的35例(54.7%)检测到微转移。通过RT-PCR分析,CEA mRNA呈现阳性条带的患者在无病生存期和总生存期方面的预后均明显差于RT-PCR阴性的患者(分别为P = 0.027和0.015)。通过IHC分析,微转移的存在在无病生存期或总生存期方面均不能预测患者的预后。在各种临床或病理因素中,肿瘤生长特征的浸润模式与较短的无病生存期显著相关。通过多因素Cox回归分析,RT-PCR检测到的微转移和克罗恩样淋巴反应均为独立的预后因素。
通过RT-PCR而非IHC检测到的微转移,在识别可能有CRC复发高风险且可能因此从全身辅助治疗中获益的患者方面可能具有临床价值。